Mouse microglia got a genetic tune-up. On 9 June in Nature Aging, researchers led by Warren G. Tourtellotte at Cedars-Sinai Medical Center in Los Angeles reported that expressing human ...

This study investigates potential therapeutic targets for osteoporosis using a multiomics approach and explores the dual role of androgen receptor (AR) signaling in its pathophysiology. By analyzing ...

Ginsenoside RK1 Promotes Hepatic Stellate Cell Glycolysis-Mediated Ferroptosis by Activating the HK2/ACSL4/LPCAT3/ALOX5 Signaling Pathway ...

If we can show that glutamate signaling eventually makes the ALS motor neurons sick, for instance, we can apply drugs to the blood vessel side of the chip to mimic a clinical trial.

Sanofi has licensed gusacitinib, an oral JAK/SYK dual inhibitor from the “AI-native” drug development company Formation Bio, marking the pharma’s latest investment in AI-focused drug development.

Having secured one of last year’s largest funding rounds, Formation Bio is eyeing up to 545 million euros from a licensing deal with Sanofi.